Improving outcomes in type 2 diabetes; a role for GLP-1 RA?

Despite recent advances in glucose-lowering therapies, rates of cardiovascular disease and mortality in people with type 2 diabetes, about 90% of whom have obesity or overweight, still remain high. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven good efficacy in glycaemic control and weight loss in patients with T2D. Furthermore, recent cardiovascular outcome trials suggest that a few GLP-1RAs have demonstrated cardiovascular benefits in patients with T2D and established or high-risk cardiovascular disease, resulting in recent updates of treatment labels and national and international guidelines.
In this session, Dr Seidu will give an overview of different GLP-1RA therapies and their place in the treatment pathway for patients with T2D and high cardiovascular risk.

Learning outcomes:

  • To discuss the link between type 2 diabetes, obesity and cardiovascular disease
  • To provide an overview of recent cardiovascular outcome trial results
  • To describe the different GLP-1RAs therapies available and discuss their optimal placing in the management of patient with type 2 diabetes and high cardiovascular risk

This session has been organised and funded by Novo Nordisk

Thursday 15th November 2018

15:55 - 16:25

Primary, Community & Specialist Care

Prescribing Icon

Speakers

Head of Research, Primary Care Diabetes Europe and primary care research fellow in diabetes at the University of Leicester, Hockley Farm Medical Practice, University of Leicester, Leicester Diabetes Centre

Our site is intended for UK Healthcare Professionals

Are you a UK Healthcare Professional?

We’re sending you to our partner charity’s site. 

DRWF provide information and support for people with diabetes and their friends & families